Zealand Pharma A/S (ZLDPF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Adam Sinding Steensberg M.D.
|
President & CEO | 3.38M | -- | 1974 |
|
Ms. Henriette Wennicke
|
EVP & CFO | 1.52M | -- | 1983 |
|
Mr. Ivan Mourits Moller
|
Executive VP & COO | -- | -- | -- |
|
Mr. Utpal Singh
|
Executive VP & Chief Scientific Officer | -- | -- | 1974 |
|
Mr. Eric Rojas
|
VP & Head of Investor Relations | -- | -- | -- |
|
Mr. Ravinder Singh Chahil
|
EVP & General Counsel | -- | -- | 1968 |
|
Ms. Christina Sonnenborg Bredal
|
Executive VP & Chief People Officer | -- | -- | 1985 |
|
Dr. Jens Damsgaard Mikkelsen M.D.
|
Head of Molecular Pharmacology | -- | -- | -- |
|
Dr. David M. Kendall M.D.
|
Executive VP, Chief Medical Officer & Head of R&D | -- | -- | 1961 |
|
Mr. Eric Cox
|
Executive VP & Chief Commercial Officer | -- | -- | 1967 |
Zealand Pharma A/S
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 578
Description
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Corporate Governance
Upcoming Events
November 12, 2026 at 9:00 PM UTC
Zealand Pharma A/S Earnings Date
Recent Events
Recent Events Information Not Available
